The telomere length landscape of prostate cancer
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Ewing Sarcoma-Derived Extracellular Vesicles Impair Dendritic Cell Maturation and Function
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Detection of the novel SARS-CoV-2 European lineage B.1.177 in Ontario, Canada
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
Home » Archives for Helena Nunes » Page 3
Categories
Categories
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer
Top Posts
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples
- RBFOX2 Modulates a Metastatic Signature of Alternative Splicing in Pancreatic Cancer
- Early Changes in Tumor-Naive Cell-Free Methylomes and Fragmentomes Predict Outcomes in Pembrolizumab-Treated Solid Tumors
- Early Cancer Detection in Li–Fraumeni Syndrome with Cell-Free DNA.
- A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer